Status: Recruiting
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors
Participants needed: 149
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Samsung Bioepis Co., Ltd.Updated: Jun 30, 2026Locations: 5
Eligibility criteria
Histologically-confirmed, locally advanced (unresectable) or metastatic solid tu...
Have spinal cord compression or clinically active central nervous system metasta... [+4]